By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Hemispherx Biopharma Inc. 

One Penn Center
1617 JFK Boulevard
Philadelphia  Pennsylvania  19103  U.S.A.
Phone: 215-988-0080 Fax: 215-988-1739


SEARCH JOBS








Company News
Hemispherx Biopharma (HEB) Receives The European Patent Office Examining Division's Notice Of Intention To Grant The New Composition Of Matter Patent Covering Ampligen Formulations 6/25/2015 7:09:21 AM
Hemispherx Biopharma (HEB) To Present At The Marcum Microcap Conference In New York 5/20/2015 2:03:55 PM
Hemispherx Biopharma (HEB) Announces Financial Results For The Three Months Ended March 31, 2015 5/13/2015 10:45:14 AM
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation By The Hemispherx Biopharma (HEB) For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 5/11/2015 7:53:27 AM
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion On Application For Orphan Designation By The European Medicines Agency Agency For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 3/24/2015 7:16:43 AM
Hemispherx Biopharma (HEB) To Present Data On The Activity Of Ampligen(R) Against The Ebola Virus 3/23/2015 7:38:24 AM
Hemispherx Biopharma (HEB) Announces Financial Results For The Year Ended December 31, 2014 3/20/2015 7:33:52 AM
Hemispherx Biopharma (HEB) Enters A Collaboration With Emerge Health For The Commercialization Of Ampligen For Chronic Fatigue Syndrome (CFS) In Australia And New Zealand 3/9/2015 7:37:16 AM
Hemispherx Biopharma (HEB) Announces The Completion Of The Newly Upgraded Alferon Facility: Commercial Production Of Alferon Is In The Final Stage Integrating Continuous Flow Manufacturing Technology 3/2/2015 7:14:42 AM
Hemispherx Biopharma (HEB): Institute Of Medicine, The Health Arm Of The US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) As A "Systemic Exertion Intolerance Disease" (SEID) 2/23/2015 7:31:14 AM
12345678910...
//-->